Maxim analyst Jason McCarthy lowered the firm’s price target on Reviva Pharmaceuticals (RVPH) to $2 from $5 and keeps a Buy rating on the shares, citing dilution for the lowered target following the company’s Q2 update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVPH: